Bruker Unveils High-Throughput MyGenius PRO for Infectious Disease Diagnostics
Event summary
- Bruker launched MyGenius PRO®, a fully automated, high-throughput sample-to-answer molecular diagnostics system at ESCMID Global 2026.
- The system supports continuous loading of samples, consumables, and reagents, and offers random-access operation.
- Initial IVDR menu includes assays for CMV, EBV, and BKV, with plans to expand to HIV-1, HBV, HCV, and HHV-6 in 2026.
- Developed in collaboration with ELITechGroup and Hitachi High-Tech, with Hitachi High-Tech introducing the platform in Japan under the tradename LABOSPECT GA-5.
The big picture
Bruker's launch of MyGenius PRO® underscores the growing demand for automated, high-throughput molecular diagnostics in infectious disease testing. The collaboration with Hitachi High-Tech expands Bruker's reach into the Japanese market, while the system's compliance with IVDR regulations positions it for broader European adoption. The strategic focus on high-throughput solutions aligns with industry trends towards streamlined laboratory workflows and faster clinical response times.
What we're watching
- Menu Expansion
- The pace at which Bruker expands its IVDR assay menu will determine the system's market penetration and competitive positioning.
- Regulatory Compliance
- Whether Bruker can sustain compliance with IVDR regulations while rapidly expanding its assay offerings.
- Market Adoption
- How the high-throughput capabilities of MyGenius PRO will affect adoption in high-volume diagnostic laboratories.
Related topics